Schott Pharma is investing more than 100 million euros in its existing site in Lukácsháza, Hungary, to expand capacity for sterile ready-to-use (RTU) cartridges.
Following the opening of a production facility for prefillable glass syringes in 2024, the company has now laid the foundation stone for a further plant at the site, which will create production capacity for high-value solutions (HVS).
This step is part of the company's expansion strategy to increase the share of sales accounted for by these high-margin products.
„To meet the growing demand, we are expanding our capacities and our presence in the diabetes and obesity sector. That is why we are investing more than 100 million euros in our plant in Hungary.“
Andreas Reisse, CEO of Schott Pharma
Sterile cartridges are used for the administration of biologics, GLP-1 drugs, insulin or hormone therapies for the treatment of diabetes, obesity or immune disorders. The new plant will create more than 100 additional jobs in the region.
The Schott Pharma site in Lukácsháza already plays an important role in supplying the global pharmaceutical industry with solutions for the storage and administration of medicines. Only last year the company opened a new, state-of-the-art production facility for prefillable glass syringes at the site, which are used for GLP-1 drugs, critical vaccines or biologics. Since then, production has started with 120 new employees and additional production capacity has been created.
With ready-to-use cartridges, the company intends to create additional production capacity for high-value solutions at the site, which has sufficient space to support the company's growth strategy, according to the Mainz-based company.
After St. Gallen in Switzerland Lukácsháza will be the second Schott Pharma site to manufacture sterile cartridges.
Source: Schott Pharma
